<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8632DBC8-D226-4232-936B-A8AD6728ED45"><gtr:id>8632DBC8-D226-4232-936B-A8AD6728ED45</gtr:id><gtr:name>Pharmaleads</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3C03463-3705-4E3B-A5AE-F754BF00EE9C"><gtr:id>C3C03463-3705-4E3B-A5AE-F754BF00EE9C</gtr:id><gtr:name>Debiopharm</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8632DBC8-D226-4232-936B-A8AD6728ED45"><gtr:id>8632DBC8-D226-4232-936B-A8AD6728ED45</gtr:id><gtr:name>Pharmaleads</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3C03463-3705-4E3B-A5AE-F754BF00EE9C"><gtr:id>C3C03463-3705-4E3B-A5AE-F754BF00EE9C</gtr:id><gtr:name>Debiopharm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A0740019-B847-40B7-8504-8AA5AF6E45FC"><gtr:id>A0740019-B847-40B7-8504-8AA5AF6E45FC</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Kenneth</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CCBAB667-6A4F-4A6F-A2C8-5ADBDD905D6D"><gtr:id>CCBAB667-6A4F-4A6F-A2C8-5ADBDD905D6D</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Stanley</gtr:otherNames><gtr:surname>Talbot</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D198AA54-9F54-4FF0-A45A-226FC45111FF"><gtr:id>D198AA54-9F54-4FF0-A45A-226FC45111FF</gtr:id><gtr:firstName>Karl</gtr:firstName><gtr:surname>Herholz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/71861E3B-A21F-4A75-A6FE-DA6407DFF3E0"><gtr:id>71861E3B-A21F-4A75-A6FE-DA6407DFF3E0</gtr:id><gtr:firstName>Wael</gtr:firstName><gtr:surname>El-Deredy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800522"><gtr:id>4A2B8156-7D7D-45B2-89D8-3C39470C042F</gtr:id><gtr:title>Osteoarthritis: Interactions between endogenous brain opioids and the physiological and psychological responses to pain.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800522</gtr:grantReference><gtr:abstractText>About 15% of the population have health problems due to arthritis and other associated conditions. The most common type of arthritis is osteoarthritis. The main reason why people with osteoarthritis go to see a doctor is pain. Pain is also the main reason why people with osteoarthritis lose their mobility. However the type of treatments available for people with osteoarthritis are very limited. Our research group has carried out studies that have shown that pain from osteoarthritis has an emotional effect on the brain that affects how pain is felt. This emotional effect could make a big difference to how patients respond to treatment or surgery. By reducing the effects of these emotions we could reduce how unpleasant the pain feels. This could also help to keep more people mobile. Our research aims to investigate how emotions such as anxiety and distress which affects how we feel pain, are altered by the natural painkillers made by the brain (opiates). We would like to approach people with osteoarthritis and ask them to take part in our study. Specifically, we would like to test a variety of people with different levels of anxiety and distress. We will make use of techniques that can produce images of the brain to measure the naturally occurring brain opiates, and how they affect how we expect (anticipate) and feel (give attention to) pain. These studies will help us explain how different people experience pain and why they respond differently to treatments. In the long term, they will also help us understand how the brains own painkillers work, and how we can improve on existing treatments for pain from osteoarthritis and also develop new therapies.</gtr:abstractText><gtr:technicalSummary>Pain is the main cause of disability in patients with osteoarthritis (OA). However, there is a highly variable relationship between joint damage and the corresponding pain experience. We have established the brain structures that process pain in OA, and showed a greater response in areas concerned with affective processing such as the anterior cingulate cortex, prefrontal cortex, amygdala, hypothalamus and anterior insula.
These area are known to show changes in mu-opioid receptor availability in response to pain stimulation. We propose to study the effects of endogenous opioids (EO?s) in reducing pain processing within these brain areas. We will measure changes in opioid receptor binding in the brain to determine the brains production of EO?s in response to pain. We will assess: 1/ whether this is reduced in OA patients with psychological distress and 2/ if this correlates with altered ability to anticipate pain and switch attention away from the unpleasantness of pain. This will provide a step-change in our understanding of the physiology of pain perception in OA. It will facilitate more rational approaches to new therapies and existing treatments.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>785880</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Debiopharm</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Development of enkephalinase inhibitors</gtr:description><gtr:id>A909F7D1-A1A1-42BB-82F8-532922D0A530</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>D3M5sYxzeLY-2</gtr:outcomeId><gtr:partnerContribution>Advice and support moving forward towards phase 2 clinical trial in chronic pain</gtr:partnerContribution><gtr:piContribution>Discussion of enkephalinase inhibitors designed for better brain penetration</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pharmaleads</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Development of enkephalinase inhibitors</gtr:description><gtr:id>0EF2ADE4-705C-465C-9B65-7F02E114B5A2</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>D3M5sYxzeLY-1</gtr:outcomeId><gtr:partnerContribution>Advice and support moving forward towards phase 2 clinical trial in chronic pain</gtr:partnerContribution><gtr:piContribution>Discussion of enkephalinase inhibitors designed for better brain penetration</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Radiolabelled diprenorphine will be used as a radiotracer in our PET study. Displacement of diprenorphine from opioid receptors is a method of measuring the release of endogenous opioids, which compete with diprenorphine for binding to their receptors.</gtr:description><gtr:id>EF282046-E766-4763-BDEE-298056444D63</gtr:id><gtr:impact>This material will be used as part of a PhD degree by someone within the University of Manchester, but outside our research group.

The material was also used as part of a research study conducted at the University of Bristol (Investigator: Hugh Sims-Williams).</gtr:impact><gtr:outcomeId>38292AC1B8F</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Radioactively labelled (carbon-11) diprenorphine</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed improved methods for separation and measurement of C11 diprenorphine metabolites.</gtr:description><gtr:id>442989F1-7E0A-4033-8EE3-CA3E8249BC6D</gtr:id><gtr:impact>We have shared it with the Hammersmith PET group and are in the process of publishing it. This will make the method substantially more reliable.</gtr:impact><gtr:outcomeId>56dd9a9ec00c02.14860099</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Improved metabolite analysis of C11 diprenorphine</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FB1BA8A6-7F57-422B-8CFA-5410E8A36842</gtr:id><gtr:title>Striatal opioid receptor availability is related to acute and chronic pain perception in arthritis: does opioid adaptation increase resilience to chronic pain?</gtr:title><gtr:parentPublicationTitle>Pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e14ad7dc46751cc03b82cf6e81f69dc"><gtr:id>9e14ad7dc46751cc03b82cf6e81f69dc</gtr:id><gtr:otherNames>Brown CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0304-3959</gtr:issn><gtr:outcomeId>56dd95e3669ec5.46221950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9780918-58D1-4FB2-9B55-87819666EA8E</gtr:id><gtr:title>The automated radiosynthesis and purification of the opioid receptor antagonist, [6-O-methyl-11C]diprenorphine on the GE TRACERlab FXFE radiochemistry module.</gtr:title><gtr:parentPublicationTitle>Journal of labelled compounds &amp; radiopharmaceuticals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f5749312eb724818dbe83054cb8a51a"><gtr:id>5f5749312eb724818dbe83054cb8a51a</gtr:id><gtr:otherNames>Fairclough M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>5464d10bf2e8c0.54057847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A49A64C-EE8E-4854-B577-3B415E69513D</gtr:id><gtr:title>People can raise pain threshold by altering brain chemistry, arthritis patients study shows</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8bdf10d2a031cf0705fc4c0a4901201"><gtr:id>e8bdf10d2a031cf0705fc4c0a4901201</gtr:id><gtr:otherNames>Christopher Brown</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dd9c7464dcb6.07070650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A08CB81-8186-42A1-9985-BE67E0A67AFF</gtr:id><gtr:title>Development of a method for the preparation of zirconium-89 radiolabelled chitosan nanoparticles as an application for leukocyte trafficking with positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f5749312eb724818dbe83054cb8a51a"><gtr:id>5f5749312eb724818dbe83054cb8a51a</gtr:id><gtr:otherNames>Fairclough M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0969-8043</gtr:issn><gtr:outcomeId>5a9eac987ec7c4.05137700</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800522</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>